Asymmetric (ADMA) and Symmetric (SDMA) Dimethylarginines in Chronic Kidney Disease: A Clinical Approach

Autor: Nestor Oliva-Damaso, José Carlos Rodríguez-Pérez, Raquel Santana-Estupiñán, Fayna González-Cabrera, Francisco Rodríguez-Esparragón, Elena Oliva-Damaso, Eduardo Baamonde-Laborda, Juan Payan
Jazyk: angličtina
Rok vydání: 2019
Předmět:
0301 basic medicine
Aging
medicine.medical_treatment
asymmetric dimethylarginine
Review
Disease
030204 cardiovascular system & hematology
lcsh:Chemistry
chemistry.chemical_compound
0302 clinical medicine
uremia
SDMA
Molecular Targeted Therapy
lcsh:QH301-705.5
Spectroscopy
end-stage renal disease
biology
symmetric dimethylarginine
cardiovascular
General Medicine
Prognosis
Computer Science Applications
Nitric oxide synthase
Cardiovascular Diseases
Metabolic Networks and Pathways
medicine.medical_specialty
Renal function
Arginine
Catalysis
End stage renal disease
Inorganic Chemistry
03 medical and health sciences
Renal Dialysis
Internal medicine
medicine
Animals
Humans
Renal Insufficiency
Chronic
Physical and Theoretical Chemistry
methylarginines
Molecular Biology
Dialysis
business.industry
Organic Chemistry
medicine.disease
Uremia
ADMA
030104 developmental biology
Endocrinology
chemistry
lcsh:Biology (General)
lcsh:QD1-999
biology.protein
Endothelium
Vascular
business
Asymmetric dimethylarginine
chronic kidney disease
Kidney disease
Zdroj: International Journal of Molecular Sciences, Vol 20, Iss 15, p 3668 (2019)
International Journal of Molecular Sciences
ISSN: 1422-0067
Popis: Asymmetric dimethylarginine (ADMA) and its enantiomer, Symmetric dimethylarginine (SDMA), are naturally occurring amino acids that were first isolated and characterized in human urine in 1970. ADMA is the most potent endogenous inhibitor of nitric oxide synthase (NOS), with higher levels in patients with end-stage renal disease (ESRD). ADMA has shown to be a significant predictor of cardiovascular outcome and mortality among dialysis patients. On the other hand, although initially SDMA was thought to be an innocuous molecule, we now know that it is an outstanding marker of renal function both in human and in animal models, with ESRD patients on dialysis showing the highest SDMA levels. Today, we know that ADMA and SDMA are not only uremic toxins but also independent risk markers for mortality and cardiovascular disease (CVD). In this review, we summarize the role of both ADMA and SDMA in chronic kidney disease along with other cardiovascular risk factors.
Databáze: OpenAIRE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje